BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort

Launched by WOMEN'S COLLEGE HOSPITAL · Mar 23, 2021

Keywords

ClinConnect Summary

The BROadband vs Narrowband photoTherapy for Eczema Trial is a study designed to compare two types of light therapy—Broadband and Narrowband ultraviolet B phototherapy—to see which one works better for treating eczema, a common skin condition that can be challenging to manage. The research will take place at three centers in Canada, and it aims to gather important information about how severe patients' eczema is and which treatments they have tried. Participants will also provide blood and skin samples to help researchers understand the causes of eczema better.

To join the study, individuals must have moderate to severe eczema that hasn't improved with standard treatments. They should be between the ages of 6 and 74 and meet specific criteria for their eczema severity. Participants can expect to receive one of the two types of light therapy and will be closely monitored throughout the trial. This study is important because it aims to improve existing treatments and pave the way for new therapies for eczema.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Atopic dermatitis according to the Hanifin and Rajka criteria.
• • 2. Validated Investigator Global Assessment score of 3 or 4 out of 4
• • 3. Eczema Area and Severity Index (EASI) score ≥7.1
• • 4. Moderate to severe disease as above despite an adequate trial of topical therapy.
• Exclusion Criteria:
• • 1. Treatment with phototherapy or oral systemic immune-modulating agents (cyclosporine, methotrexate, azathioprine, mycophenolate) less than 30 days before baseline.
• • 2. Treatment with systemic biologic (dupilumab) or experimental therapeutic less than 90 days before baseline.
• • 3. Current treatment with oral or intramuscular corticosteroids within 30 days prior to baseline. Topical, intralesional or inhaled corticosteroids are allowed.
• • 4. Participating in a clinical trial assessing an investigational agent for atopic dermatitis (topical, systemic or device) within 90 days prior to enrollment.